ABG Management Ltd. - 22 Oct 2025 Form 4 Insider Report for ProMIS Neurosciences Inc. (PMN)

Reporting relationship: 10%+ Owner
Issuer ticker: PMN
Reported as of: 22 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Oct 2025, 16:34:08 UTC
Prior SEC filing: 04 Aug 2025
Next SEC filing: 05 Feb 2026
Source filing: View source filing
Reporting owner signature: ABG Management Ltd., By: /s/ Fan Yu, Director

Key filing fact

ABG Management Ltd. filed Form 4 for ProMIS Neurosciences Inc. (PMN) on 24 Oct 2025.

Key facts

This page summarizes ABG Management Ltd.'s Form 4 filing for ProMIS Neurosciences Inc. (PMN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 Oct 2025, 16:34.

Change

Previous filing in this sequence was filed on 04 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (5)

CIK 0001832106 Primary reporting owner

ABG Management Ltd.

Relationship: 10%+ Owner
Address: #3902, 39/F, E TOWER,, 10 HARCOURT RD CTR, HONG KONG, HONG KONG
Signature: ABG Management Ltd., By: /s/ Fan Yu, Director
Signature date: 24 Oct 2025

CIK 0001831963

Ally Bridge MedAlpha Master Fund L.P.

Relationship: 10%+ Owner
Address: C/O MAPLES CORPORATE SERVICES LIMITED,, P.O. BOX 309, UGLAND HOUSE,, GRAND CAYMAN, CAYMAN ISLANDS
Signature: Ally Bridge MedAlpha Master Fund L.P., By: Ally Bridge Group (NY) LLC, its manager, By: ABG Management Ltd., its managing member, By: /s/ Fan Yu, Director
Signature date: 24 Oct 2025

CIK 0001822947

Ally Bridge Group (NY) LLC

Relationship: 10%+ Owner
Address: 430 PARK AVENUE, 12TH FLOOR, NEW YORK,
Signature: Ally Bridge Group (NY) LLC, By: ABG Management Ltd., its managing member, By: /s/ Fan Yu, Director
Signature date: 24 Oct 2025

CIK 0001668029

Yu Fan

Relationship: 10%+ Owner
Address: #3902, 39/F, E TOWER,, 10 HARCOURT RD CTR, HONG KONG, HONG KONG
Signature: /s/ Fan Yu
Signature date: 24 Oct 2025

CIK 0002092283

Alex Slanix Paul

Relationship: Director
Address: C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO,, ONTARIO, CANADA
Signature: /s/ Max A. Milbury, Attorney-in-Fact for Slanix Paul Alex
Signature date: 24 Oct 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PMN transaction Derivative

Option (right to buy)

Award

Transaction value: $0
Shares: +40,000
Change %
Price: $0.000000
Shares after: 40,000
Date: 22 Oct 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 40,000
Exercise price: $0.4500
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

25% of the shares subject to this option vested on the date of grant and the remaining shares shall vest in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Footnote F2

This option was granted to Slanix Alex, a director of the Issuer and an employee of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. Dr. Alex holds any equity-based compensation awarded to him for his service as a director of the Issuer for the benefit of Ally Bridge MedAlpha Master Fund L.P. Any proceeds from the sale of shares upon exercise of this award shall be remitted to Ally Bridge MedAlpha Master Fund L.P. The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such securities are beneficially owned by him for Section 16 or any other purpose.